Compare INCR & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INCR | NSRX |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.4M | 53.5M |
| IPO Year | 2021 | N/A |
| Metric | INCR | NSRX |
|---|---|---|
| Price | $0.77 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $20.50 |
| AVG Volume (30 Days) | 32.5K | ★ 142.6K |
| Earning Date | 03-30-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $69.54 | N/A |
| Revenue Next Year | $41.75 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.68 | $2.40 |
| 52 Week High | $1.77 | $9.99 |
| Indicator | INCR | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.83 | 26.47 |
| Support Level | $0.76 | N/A |
| Resistance Level | $0.88 | $5.20 |
| Average True Range (ATR) | 0.04 | 0.42 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 30.36 | 6.35 |
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.